Prospective Longitudinal ctDNA Workflow Reveals Clinically Actionable Alterations in Ovarian Cancer

Jaana Oikkonen, PhD1; Kaiyang Zhang, MSc1; Liina Salminen, MD2; Ingrid Schulman1; Kari Lavikka1; Noora Andersson, PhD1; Erika Ojanperä1; Sakari Hietanen, MD, PhD2; Seija Grénman, MD, PhD2; Rainer Lehtonen, PhD1; Kaisa Huhtinen, PhD3; Olli Carpén, MD, PhD1,3,4; Johanna Hynninen, MD, PhD2; Anniina Färlkilä, MD, PhD1,4,5; and Sampsa Hautaniemi, D Tech1

PURPOSE Circulating tumor DNA (ctDNA) detection is a minimally invasive technique that offers dynamic molecular snapshots of genomic alterations in cancer. Although ctDNA markers can be used for early detection of cancers or for monitoring treatment efficacy, the value of ctDNA in guiding treatment decisions in solid cancers is controversial. Here, we monitored ctDNA to detect clinically actionable alterations during treatment of high-grade serous ovarian cancer, the most common and aggressive form of epithelial ovarian cancer with a 5-year survival rate of 43%.

PATIENTS AND METHODS We implemented a clinical ctDNA workflow to detect clinically actionable alterations in more than 500 cancer-related genes. We applied the workflow to a prospective cohort consisting of 78 ctDNA samples from 12 patients with high-grade serous ovarian cancer before, during, and after treatment. These longitudinal data sets were analyzed using our open-access ctDNA-tailored bioinformatics analysis pipeline and in-house Translational Oncology Knowledgebase to detect clinically actionable genomic alterations. The alterations were ranked according to the European Society for Medical Oncology scale for clinical actionability of molecular targets.

RESULTS Our results show good concordance of mutations and copy number alterations in ctDNA and tumor samples, and alterations associated with clinically available drugs were detected in seven patients (58%). Treatment of one chemoresistant patient was changed on the basis of detection of ERBB2 amplification, and this ctDNA-guided decision was followed by significant tumor shrinkage and complete normalization of the cancer antigen 125 tumor marker.

CONCLUSION Our results demonstrate a proof of concept for using ctDNA to guide clinical decisions. Furthermore, our results show that longitudinal ctDNA samples can be used to identify poor-responding patients after first cycles of chemotherapy. We provide what we believe to be the first comprehensive, open-source ctDNA workflow for detecting clinically actionable alterations in solid cancers.

INTRODUCTION Effective treatment of metastatic solid cancers is hampered by intrapatient heterogeneity, tumor evolution, and the paucity of representative tissue samples to guide treatment decisions. Analysis of circulating tumor DNA (ctDNA) is an approach with the potential of overcoming all three obstacles.1 Indeed, ctDNA sampling is a clinically attractive, minimally invasive technique that is based on the observation that tumor cells leak DNA to the bloodstream, where it can be captured by genomic assays. ctDNA can be used to monitor tumor evolution,2 detect cancer early,3 and monitor treatment efficacy.4 However, the value of ctDNA in guiding treatment decisions still remains controversial,1 especially in cancers lacking dominant oncogenic mutations.

A major reason for controversy in the use of ctDNA to guide clinical decision making stems from the varying, and often poorly described, analysis approaches.5 Translating genomic alterations in ctDNA data into a clinical decision requires multidisciplinary expertise in medical genetics, bioinformatics, and clinical oncology, as discussed in response to a recent study.6 Another reason is that most earlier studies focused on a few or tens of candidate genes, which significantly decreases the probability of finding an effective therapy on the basis of ctDNA data, whereas exome or whole-genome ctDNA sequencing is currently too expensive for clinical use.

Here, we present a comprehensive ctDNA analysis approach that consists of longitudinal ctDNA sampling, a panel of more than 500 cancer-related genes,
The aim of the study was to identify the clinical usefulness of circulating tumor DNA (ctDNA) in the treatment of high-grade serous ovarian cancer (HGSOC) and to provide a clinical workflow for reliable detection of ctDNA alterations.

Key Objective
The early detection of poor-responding patients allows the design of alternative treatment strategies in HGSOC. Especially for platinum-resistant patients who have limited treatment options, rapid discovery of resistant cell populations can provide an early opportunity to interfere with the development of recurrence. The provided approach allows the selection of treatment options that target subclones that persist during therapy. This is a substantial improvement in the management of recurrent solid cancers, where tumors are not usually sampled either because of the risk of potential intervention complications or simply because the sample could be insufficient or not representative of the disease.

CONTEXT
We show that longitudinal ctDNA sampling can be used to detect response to platinum-taxane primary therapy after the first cycles of chemotherapy and to identify clinically applicable mutations and copy number alterations. In one patient with chemoresistant HGSOC, ctDNA-guided treatment including trastuzumab was administered during tumor progression and yielded tumor shrinkage.

Knowledge Generated
The early detection of poor-responding patients allows the design of alternative treatment strategies in HGSOC. Especially for platinum-resistant patients who have limited treatment options, rapid discovery of resistant cell populations can provide an early opportunity to interfere with the development of recurrence. The provided approach allows the selection of treatment options that target subclones that persist during therapy. This is a substantial improvement in the management of recurrent solid cancers, where tumors are not usually sampled either because of the risk of potential intervention complications or simply because the sample could be insufficient or not representative of the disease.

Relevance
We prospectively collected 78 plasma samples from 12 patients treated for ovarian or primary peritoneal HGSOC at Turku University Hospital, Finland (Table 1 and Data Supplement). Patients were treated either with primary debulking surgery (PDS) followed by a median of six cycles (range, five to six cycles) of platinum-taxane chemotherapy, or with neoadjuvant chemotherapy (NACT), where the primary operation was laparoscopic evaluation with diagnostic tumor sampling, followed by three cycles of carboplatin and paclitaxel (Data Supplement). In these patients, an interval debulking surgery (IDS) was performed after NACT, aimed at complete cytoreduction, followed by a median of three cycles (range, three to six cycles) of adjuvant chemotherapy.

Patients
We prospectively collected 78 plasma samples from 12 patients treated for ovarian or primary peritoneal HGSOC at Turku University Hospital, Finland (Table 1 and Data Supplement). Patients were treated either with primary debulking surgery (PDS) followed by a median of six cycles (range, five to six cycles) of platinum-taxane chemotherapy, or with neoadjuvant chemotherapy (NACT), where the primary operation was laparoscopic evaluation with diagnostic tumor sampling, followed by three cycles of carboplatin and paclitaxel (Data Supplement). In these patients, an interval debulking surgery (IDS) was performed after NACT, aimed at complete cytoreduction, followed by a median of three cycles (range, three to six cycles) of adjuvant chemotherapy.

Patients were stratified into poor and good responders on the basis of the platinum-free interval (PFI).9 Patients with platinum-resistant (PFI, less than 6 months; n = 3) or partially platinum-sensitive (PFI, 6 to 12 months; n = 3) disease were regarded as poor responders (50%), whereas patients with platinum-sensitive disease (PFI, greater than 12; n = 6) were considered good responders (Table 1 and Data Supplement).

All patients participating in the study gave their informed consent, and the study was approved by the Ethics Committee of the Hospital District of Southwest Finland.

Sample Preparation and Sequencing
Venous whole blood (5 to 6 mL) was collected into an EDTA tube, shaken eight to 10 times, and centrifuged twice for 10 minutes at 2000 × g. The samples were stored at −80°C as 1 to 2 mL aliquots frozen less than 2 hours after collection to avoid lysis of the white blood cells.1 Cell-free DNA (cfDNA) was extracted from plasma samples and subjected to 1000x targeted Illuma Hi-Seq sequencing at BGI (BGI Europe A/S, Copenhagen, Denmark) using the Oseq Solid Cancer Panel with more than 500 clinically actionable genes (Data Supplement).

DNA was isolated from 21 liquid LN2 snap-frozen tumor tissue and ascites samples (Data Supplement), as well as from whole blood (germline) buffy coat samples, and was sequenced using the Oseq panel with coverage of 200x.

Mutation and Copy Number Detection
Mutation detection was performed in the computational ecosystem Anduril10 using the ctDNA data analysis pipeline, which is based on best practices for sequencing data analysis (Data Supplement). A detailed description of the pipeline and validation data can be found in the Data Supplement. Briefly, somatic single nucleotide variants (SNVs) and indels were detected using Mutect2.11 We
Residual disease after debulking surgery (DS) was reported as the surgeon
chemotherapy; PDS, primary debulking surgery; PFI, platinum-free interval; PFS, HGSOC, high-grade serous ovarian cancer; NACT, neoadjuvant platinum-paclitaxel
destimation on the amount of macroscopic tumor. The primary therapy response was

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>PFI &lt; 12 months</th>
<th>PFI ≥ 12 months</th>
<th>Total Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment strategy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PDS</td>
<td>1</td>
<td>5</td>
<td>6</td>
</tr>
<tr>
<td>NACT</td>
<td>5</td>
<td>1</td>
<td>6</td>
</tr>
<tr>
<td>Tumor stage (FIGO 2014)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IIIB</td>
<td>0</td>
<td>1</td>
<td>1 (8)</td>
</tr>
<tr>
<td>IIIC</td>
<td>4</td>
<td>5</td>
<td>9 (75)</td>
</tr>
<tr>
<td>IVA</td>
<td>1</td>
<td>0</td>
<td>1 (8)</td>
</tr>
<tr>
<td>IVB</td>
<td>1</td>
<td>0</td>
<td>1 (8)</td>
</tr>
<tr>
<td>Residual tumor after DS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>4</td>
<td>4</td>
<td>8 (67)</td>
</tr>
<tr>
<td>1-10 mm</td>
<td>1</td>
<td>1</td>
<td>2 (17)</td>
</tr>
<tr>
<td>&gt; 10 mm</td>
<td>1</td>
<td>1</td>
<td>2 (17)</td>
</tr>
<tr>
<td>Primary therapy outcome</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Complete</td>
<td>3</td>
<td>5</td>
<td>8 (67)</td>
</tr>
<tr>
<td>Partial</td>
<td>2</td>
<td>1</td>
<td>3 (25)</td>
</tr>
<tr>
<td>Progressive</td>
<td>1</td>
<td>0</td>
<td>1 (8)</td>
</tr>
<tr>
<td>PFS, months</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>6.9 to 14.2</td>
<td>18 to &gt; 25</td>
<td>6.9 to &gt; 25</td>
</tr>
<tr>
<td>Age at diagnosis, years</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>66.5</td>
<td>70.0</td>
<td>68.0</td>
</tr>
</tbody>
</table>

NOTE. Data are presented as No. or No. (%) unless otherwise indicated. Residual disease after debulking surgery (DS) was reported as the surgeon’s visual estimation on the amount of macroscopic tumor. The primary therapy response was defined according to RECIST 1.1.

Abbreviations: FIGO, International Federation of Gynecology and Obstetrics; HGSOC, high-grade serous ovarian cancer; NACT, neoadjuvant platinum-paclitaxel chemotherapy; PDS, primary debulking surgery; PFI, platinum-free interval; PFS, progression-free survival.

Variants during treatment compared with the pretreatment sample (P < .01, Fisher’s exact test). Because of varying numbers of mutations in the pretreatment samples, the proportion of significantly decreased variants was corrected for mutation counts.

Pathway analysis was performed for genes with a non-decreasing mutation frequency (P < .01, Fisher’s exact test; Data Supplement) using the ConsensusPathDB tool. The ConsensusPathDB integrates data from 32 databases and allows comprehensive over-representation analysis for mutations.

**Immunohistochemistry and In Situ Hybridization**

Potentially clinically actionable alterations were validated through immunohistochemistry (IHC) and in situ hybridization for alterations classified as most prominent (ESCAT, the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets) and shown to exist in patients’ tumor tissue (Data Supplement).

**RESULTS**

cDNA Panel Reliably Captures Mutations and CNAs

We collected 78 longitudinal cDNA samples and 21 tumor tissue samples from 12 unselected patients with HGSOC (Data Supplement). We applied a sequencing panel of more than 500 genes, followed by variant and CNA calling, filtering, and prioritization of clinically relevant aberrations as shown in Fig 1A and the Data Supplement. The motivation for cDNA analysis was to perform a minimally invasive genomic survey of clinically actionable tumor aberrations in the patient. To establish this connection, we used tumor tissue samples as a ground truth for patient mutational burden. Altogether, 265 mutations in 185 genes (Data Supplement) and CNA aberrations in 113 genes (Data Supplement) passed our calling and filtering criteria.

The median concordance of mutations detected from plasma to tumor tissue samples from the same patient was 79% (Fig 1B; Data Supplement). Similar median concordance (74%) was observed with CNAs for high tumor content (greater than 30%) plasma samples (Data Supplement). Mutations in the TP53 gene are reported in nearly 100% of patients with HGSOC. In our cohort, TP53 mutations were observed in all patients. We noted, consistent with previous studies, a moderate positive correlation between cDNA TP53 VAF and serum cancer antigen 125 (CA-125; IU/mL) levels (median, 0.67; range, 0.16 to 0.97; Fig 2; Data Supplement). The number of detected CNAs highly correlated with the proportion of cDNA from cDNA (n = 101; correlation coefficient, 0.88; Data Supplement), consistent with earlier studies. These results show that the mutations and CNAs detected from plasma are in good concordance with those detected from tissue samples, which is the prerequisite for the use of detected mutations and CNAs from cDNA in clinical decision making.
CtDNA Mutation Profiles Reflect Long-Term Treatment Response and Reveal Targetable Pathways in Patients With Aggressive HGSOC

CtDNA allows several ways to monitor treatment response. For HGSOC, Parkinson et al. suggested the use of TP53 measured from ctDNA in disease monitoring. We observed that, consistent with their results, TP53 VAF was below 0.5% in all except one patient during primary chemotherapy and was increased in all patients at disease progression (Fig 2). Although the mutation profiles within a patient were relatively stable (Data Supplement), the good-responding patients showed significantly fewer mutations and a higher proportion of mutations with decreasing VAF when compared with the poor-responding...
patients ($P = .008; \text{Fig 1C}$). Importantly, changes in the ctDNA mutation frequencies were generally observed early, typically during the first two cycles of chemotherapy (Data Supplement). These results suggest that the changes in VAFs detected from ctDNA samples can be used for the early identification of patients with poor response to chemotherapy.

We hypothesized that genes whose mutation VAFs remained stable or increased during treatment in poor responders could reveal pathways crucial for chemoresistance. Pathways enriched in the poor-responding patients in comparison with the good-responding patients included transcription, p53, and chromatin regulatory pathways and DNA double-strand break repair pathways (Data Supplement). The most selectively enriched pathways in poor-responding patients were related to chromatin regulation and included 10 genes. $KMT2A$, $KMT2B$, $KMT2D$, $KDM5A$, and $SUZ12$ encode

FIG 2. Tumor burden measured by circulating tumor DNA (ctDNA), TP53, and cancer antigen 125 (CA-125) during therapy and follow-up. Tumor burden was estimated from ctDNA through TP53 variant allele frequency (VAF) (orange lines) and median VAF (blue lines). Correlation between tumor content and CA-125 was 0.67. The start of the trastuzumab treatment during progression (Prog) in patient EOC736 has been marked with a star. More detailed figures, including all treatments administered to each patient, are given in the Data Supplement. IDS, interval debulking surgery; PDS, primary debulking surgery; PTE, primary treatment end.
regulators of H3K4 histone methylation, which is reported to contribute to DNA replication fork degradation and therapy resistance.\(^{18}\) SMARCD1 and SMARCA4 encode SWI/SNF complex subunits.\(^{19}\) The pathways and herein detected mutations provide a basis for finding targets for overcoming treatment resistance.

**cT-DNA Identifies Actionable Mutations in Patients With HGSOC**

We prioritized and interpreted all 265 mutations and 113 CNAs using the Translational Oncology Knowledgebase, which integrates information from 11 databases and 14 scientific articles (Data Supplement). We identified high-confidence, potentially clinically actionable mutations or CNAs in seven patients (58%; Table 2). The Knowledgebase-prioritized mutations and CNAs revealed four major targetable processes: mammalian target of rapamycin (mTOR; patients EOC429, EOC49), DNA repair (patients EOC429, EOC677, and EOC1067), epidermal growth factor receptor (EGFR; patients EOC587, EOC736, and EOC568), and cyclin dependent kinases (CDks; patient EOC1067).

The highest allele frequency mutations matching tumor content were detected in *PTEN* (patient EOC49) and *NF1* (patient EOC429), which cause overactivation of the mTOR pathway.\(^{20,22}\) Patients with the activated mTOR pathway have been shown to be responsive to phosphatidylinositol 3-kinase/mTOR inhibitors.\(^{26}\) We validated overactivity of the mTOR pathway in the two patients with IHC from tumor tissue samples (Fig 3; Data Supplement). For patient EOC429, we also detected a *PDK1* mutation of unknown function and a *PIK3CA* amplification, which potentially cause phosphatidylinositol 3-kinase/mTOR pathway activation. Both patients with the mTOR pathway alterations responded well to platinum-based therapy (Fig 2). In patient EOC49, *PTEN* mutation VAF in omentum (8% and 6% for pretreatment and interval samples, respectively) and plasma matched the pattern of *TP53* mutation, indicating that the *PTEN* mutation exists in all tumor cells and presents an early event in tumor evolution (Data Supplement). *PTEN* was detected in a follow-up sample at 8 months after primary treatment with VAF of 0.1%, confirming its persistence during therapy.

We observed mutations and CNAs in genes associated with DNA repair in three patients. In patient EOC677, we detected mutations in *BRCA2* and *STAG2*, which potentially confer homologous recombination (HR) DNA repair deficiency and sensitivity to poly-ADP ribose polymerase (PARP) inhibitors. However, the frequencies of these mutations were low in the tumor tissues (0.2% for *BRCA2* and 3.1% for *STAG2*), suggesting subclonal events. In patient EOC429, we detected a germline deletion in *RAD51C* from plasma, which has been shown to confer HR deficiency and PARP inhibitor sensitivity.\(^{21}\) and, consistent with this, the patient had a prolonged response to platinum-based chemotherapy. We also detected a somatic deletion of *FANCA* in patient EOC1067. This patient also had concurrent deletions in *CDKN1B* and *CDKN2B*. These alterations are predicted to cause sensitivity to CDK2/4\(^{25}\) and/or CDK4/6 inhibitors.\(^{26}\) Regardless of the presence of HR-deficiency–conferring alterations, this patient, who had no residual tumor after surgery, progressed 8.9 months after the last platinum cycle.

Three patients had mutations or CNAs associated with sensitivity to drugs targeting the epidermal growth factor receptor (EGFR) pathway. Patient EOC568 had an *ERBB4* mutation, which is predicted to confer sensitivity to EGFR inhibitors.\(^{27}\) Patient EOC587 had a *MAPK* mutation and a simultaneous *MAPK1* amplification, which are associated with resistance to the EGFR targeting therapies.\(^{28,29}\) We detected a high copy-count *ERBB2* amplification in the cT-DNA in patient EOC736. The *ERBB2* locus is amplified in 3% to 11% of HGSOCs\(^{30,31}\) and is a predictive biomarker for trastuzumab. The *ERBB2* amplification was validated in primary omentum tissue using SNP genotype–based CNA detection and in the tumor tissue sample from interval debulking surgery with in situ hybridization and IHC (Figs 4A and 4B).

Patient EOC736 was treated with NACT, and she participated in a clinical trial after primary treatment, receiving maintenance bevacizumab and olaparib or placebo (Fig 4C). Although she had a clinical and radiologic complete response to primary therapy, *TP53* VAF remained detectable throughout the treatment, which, on the basis of our findings, indicates a poor response to platinum taxane (Data Supplement). Indeed, disease progression was detected only 5 months after the end of primary therapy. This patient also suffered from severe paclitaxel-induced neuropathy after primary treatment, and therefore, pegylated liposomal doxorubicin (PLD) was started at the first relapse instead of dose-dense paclitaxel therapy. PLD was discontinued after four cycles because of constantly rising CA-125 (from 193 to 769) and progression in lymph nodes as evidenced by a computed tomography scan.

On the basis of the *ERBB2* amplification detected in cT-DNA, treatment of patient EOC736 was changed to trastuzumab 600 mg subcutaneously once every 3 weeks, combined with reduced doses of carboplatin (AUC4) and dose-dense paclitaxel (80 mg/m\(^2\) on days 1 and 8). Patient responded to this combination well, and a biochemical complete response (CA-125 value reduced from 840 IU/mL to 19 IU/mL) was achieved after only three treatment cycles (Fig 4C). The response-evaluation computed tomography scan showed a notable reduction in the size of a mesenteric lesion, and partial response was achieved according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria (Fig 4D).

**DISCUSSION**

The value of cT-DNA has been demonstrated in early detection and disease monitoring, but evidence for using cT-DNA to guide clinical decision making is weaker.\(^{1}\) Herein, we present a clinical workflow that combines targeted
**TABLE 2.** Most Clinically Interesting Actionable Variants in all Patients

<table>
<thead>
<tr>
<th>Patient</th>
<th>PFI</th>
<th>Alteration</th>
<th>VAF or CNA Ratio in Plasma (% of ctDNA*)</th>
<th>VAF or CNA Ratio in Primary Tissue</th>
<th>Biologic Effect</th>
<th>Drugs Associated</th>
<th>Evidence Level</th>
<th>ESCAT Tier</th>
<th>First Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>EOC429</td>
<td>&gt; 18</td>
<td>NF1 p.Q1754X</td>
<td>0.340 (98)</td>
<td>0.556</td>
<td>PI3K/AKT/mTOR pathway activation</td>
<td>PI3K/mTOR inhibitor sensitivity</td>
<td>Late trials in other cancers</td>
<td>III</td>
<td>Philpott*16</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RAD51C del Germline</td>
<td>0.62</td>
<td>0.27</td>
<td>HR deficiency</td>
<td>PARP inhibitor sensitivity</td>
<td>Early trials for mutations in OV</td>
<td>III</td>
<td>Swisher*11</td>
</tr>
<tr>
<td>EOC49</td>
<td>&gt; 14</td>
<td>PTEN p.A333V</td>
<td>0.005 (100)</td>
<td>0.080</td>
<td>PI3K/AKT/mTOR pathway activation</td>
<td>PI3K/mTOR inhibitor sensitivity</td>
<td>Preclinical in OV; early trials in solid tumors</td>
<td>III</td>
<td>Mabuchi*20</td>
</tr>
<tr>
<td>EOC677</td>
<td>3.5</td>
<td>BRCA2 p.G602E</td>
<td>0.018 (75)</td>
<td>0.002</td>
<td>HR deficiency</td>
<td>PARP inhibitor sensitivity</td>
<td>FDA approved</td>
<td>I</td>
<td>FDA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>STAG2 p.C347F</td>
<td>0.016 (67)</td>
<td>0.031</td>
<td>HR deficiency</td>
<td>PARP inhibitor sensitivity</td>
<td>Preclinical in other cancers</td>
<td>IV</td>
<td>Bailey*23</td>
</tr>
<tr>
<td>EOC1067</td>
<td>8.9</td>
<td>FANCA del</td>
<td>0.62</td>
<td>0.41</td>
<td>HR deficiency</td>
<td>PARP inhibitor sensitivity</td>
<td>Early trials for loss-of-function variants and case report for deletion in other cancers</td>
<td>IV</td>
<td>Mateo*24</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CDKN1B del</td>
<td>0.67</td>
<td>0.70</td>
<td>Loss of cell cycle control</td>
<td>CDK2/4 inhibitor sensitivity</td>
<td>Preclinical in other cancers</td>
<td>IV</td>
<td>Stone*25</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CDKN2B del</td>
<td>0.63</td>
<td>0.42</td>
<td>Loss of cell cycle control</td>
<td>CDK4/6 inhibitor sensitivity</td>
<td>Preclinical in other cancers</td>
<td>IV</td>
<td>Cen*26</td>
</tr>
<tr>
<td>EOC736</td>
<td>5.2</td>
<td>ERBB2 amp</td>
<td>7.13</td>
<td>10.15</td>
<td>EGFR pathway activation</td>
<td>HER2 inhibitor and trastuzumab sensitivity</td>
<td>Early trials in OV; FDA approved in other cancers</td>
<td>II</td>
<td>FDA</td>
</tr>
<tr>
<td>EOC568</td>
<td>7.0</td>
<td>ERBB4 p.H374Y</td>
<td>0.009 (39)</td>
<td>0.092</td>
<td>EGFR pathway activation</td>
<td>ERBB inhibitor and lapatinib sensitivity</td>
<td>Preclinical evidence for nearby gain-of-function variants in other cancers</td>
<td>IV</td>
<td>Arteaga*27</td>
</tr>
<tr>
<td>EOC587</td>
<td>0.9</td>
<td>MAP2K1 p.A19T</td>
<td>0.111 (20)</td>
<td>0.134</td>
<td>EGFR pathway inactivation</td>
<td>EGFR inhibitor resistance</td>
<td>Case reports in other cancers</td>
<td>IV</td>
<td>Siravegna*38</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MAPK1 amp</td>
<td>2.54</td>
<td>2.74</td>
<td>EGFR pathway inactivation</td>
<td>EGFR inhibitor resistance</td>
<td>Preclinical in other cancers</td>
<td>IV</td>
<td>Ercan*29</td>
</tr>
</tbody>
</table>

**NOTE.** We prioritized detected alterations on the basis of VAFs in plasma and tissue, especially VAF dynamics in the plasma during treatment, CNA signal strength, and the Translational Oncology Knowledgebase, as well as drug evidence and relevance. All filtered mutations are shown in the Data Supplement; 31 alterations were associated with a drug, considered reliable, and did not have conflicting drug associations in the same patient. From these, the most prominent were selected for each patient, emphasizing multiple alterations affecting the same drug. The detected mutations in four patients did not pass our criteria (Data Supplement) and for one patient (EOC1099), there were no mutations associated with the existing drugs. Maximum ctDNA and primary tumor tissue VAFs are listed here for mutations. CNA ratio is from the highest tumor content ctDNA sample. Alterations are ranked according to ESCAT.16

Abbreviations: CDK, cyclin dependent kinase; CNA, copy number alteration; ctDNA, circulating tumor DNA; EGFR, epidermal growth factor receptor; ESCAT, ESMO scale for clinical actionability of molecular targets; FDA, Food and Drug Administration; HER2, human epidermal growth factor receptor 2; HR, homologous recombination; mTOR, mammalian target of rapamycin; OV, ovarian cancer; PARP, poly-ADP ribose polymerase; PFI, platinum-free interval; PI3K, phosphatidylinositol 3-kinase; VAF, variant allele frequency.

*Calculated from *TP53* VAF.
sequencing of more than 500 genes from liquid biopsies, a ctDNA data analysis pipeline, and a Translational Oncology Knowledgebase to enable longitudinal analysis of ctDNA during therapy and guide personalized cancer treatment decisions. This approach allows for reliable quantification of somatic mutations and CNAs, as well as improved detection of subclonal mutation clusters over the course of disease. The ctDNA analysis pipeline and Translational Oncology Knowledgebase are open-source and available with documentation (Data Supplement).

We detected high ctDNA–tumor congruence, which, together with the absence of alterations from the blood cells used as germline samples and comprehensive filtering of mutations through clustering, maximizes the likelihood that the reported alterations originated from tumor and not from other sources, such as clonal hematopoiesis. Indeed, our filtering approach using longitudinal samples removed false-positive alterations in all patients. Our results further emphasize the possibility that tissue samples may not represent the progressive tumor in all cases. This highlights the potential of ctDNA as a clinically feasible, noninvasive method to uncover genetic alterations and drug targets during disease progression. Thus, the optimal discovery of

**FIG 3.** Pathogenic mutation in **NF1** was detected in circulating tumor DNA (ctDNA), leading to functionally overactive mammalian target of rapamycin (mTOR) signaling in the tumor tissue. (A) Mutational frequencies in a good-responding patient (EOC429) during primary treatment and follow-up. Variant allele frequency (VAF) values are normalized for the frequency level to show relative changes in the levels. Mutational profile shows a low mutation rate because only eight mutations were detected. After the last chemotherapy cycle, **TP53** VAF declined to 0.4% from the pretreatment value of 34.6%. No novel mutations were detected during or after the treatment. The **NF1** mutation (Q1775) was detected in samples before and after primary debulking surgery (PDS) with high VAF (34% and 5.4%, respectively). The samples taken during therapy had too low a tumor burden for reliable mutation detection, and **NF1** was not detected in these subsequent samples. (B) mTOR pathway activation was detected in primary tumor tissue with higher staining for phosphorylated mTOR (pmTOR) and E4-BP1 compared with normal ovarian tissue. Scale bar, 100 μm. (C) In addition to having a complete response on the basis of RECIST 1.1, the response to primary therapy was good, as indicated by cancer antigen 125 (CA-125) values that stayed low during treatment and follow-up. A similar pattern was detected for **TP53** VAF. Median VAF shows the prolonged effect of chemotherapy. CADD, Combined Annotation Dependent Depletion; HGSOC, high-grade serous ovarian cancer; PTE, primary treatment end; 4E-BP, 4E-binding protein.
clinically useful alterations requires multiple samples from one patient combined with careful cross-disciplinary interpretation conducted by geneticists, bioinformaticians, and clinicians.

Longitudinal ctDNA sampling can be used to monitor response to first-line therapy and to identify poor-responding patients in HGSOC.4 The early hints of chemoresistance (ie, lower ratio of mutations whose frequency is reduced and...
smaller decrease of tumor burden), may be used to predict prognosis and open a window of opportunity for therapeutic interventions before disease relapse and additional evolution of the tumor. The most informative comparisons for predicting treatment outcome are samples at the preoperative stage, after two cycles of chemotherapy, and after debulking surgery, because they provide information on treatment response and on persisting tumor subclones.

We identified potentially clinically applicable mutations or CNAs in more than one half of the patients with HGSOC. These included two patients with mTOR pathway–activating mutations that were validated. Both patients had a good response to the platinum-based first-line therapy, but in the case of relapse they could most likely benefit from mTOR inhibitors alone or in combination with chemotherapy. In patient EOC429, we identified alterations conferring both mTOR pathway activation and HR deficiency, which suggests potential benefit from combination treatment with, for example, mTOR inhibition and PARP inhibition. In addition, two patients had more than one concurrent, potentially targetable alteration. Patient EOC1067 progressed after 9 months of platinum-based therapy despite the FANCA deletion conferring HR deficiency, potentially because of the contribution of the CDK alterations on cell-cycle regulation and tumor progression. On the basis of the concurrent CDKN1B and CDKN2B deletions, this patient could potentially benefit from a combination targeting both pathways, for instance, PARP inhibitor and CDK4/6 inhibitor. These results indicate that longitudinal ctDNA sampling can detect and monitor a relapse at an early stage and identify potentially effective drug combinations.

We identified a high-confidence ERBB2 amplification in the ctDNA of a patient with platinum-resistant HGSOC and used this information to change the patient’s treatment to include trastuzumab with reduced doses of platinum and paclitaxel. This patient had relapsed 5 months after primary platinum-taxane–based therapy and did not respond to PLD. Thus, rapid response to the ctDNA-guided treatment, detected by complete normalization of CA-125 values within 2 months after starting the combination treatment, was surprising. Earlier studies that have combined ERBB2 inhibitors with platinum and paclitaxel report similar encouraging responses for relapsed patients with advanced HGSOC. Although the number of patients in these studies and our study remains small because of the low number of patients with ERBB2-amplified HGSOC, these results warrant testing ERBB2 amplification from relapsed HGSOC patients with advanced disease.

tDNA sampling and sequencing with a large panel offers several benefits to physicians. Response to therapy can be inferred using two or three consecutive ctDNA samples during therapy. Rapid discovery of resistant cell population expansion provides an early opportunity to interfere with the development of recurrence. This is particularly important in chemoresistant relapse in which larger tumor burden is associated with low therapy response, with both conventional and targeted therapies. Moreover, large gene panels offer a higher probability of identifying clinically relevant mutations and CNAs, as compared with targeted approaches with a few targets. This is a substantial improvement in managing recurrent solid cancers in which tumors are not usually sampled either because of the risk of potential intervention complications or because the sample could be insufficient or not representative of the disease.

AFFILIATIONS

1Research Program in Systems Oncology, University of Helsinki, Finland
2Turku University Hospital, Turku, Finland
3Institute of Biomedicine, University of Turku, Turku, Finland
4Helsinki University Hospital, Helsinki, Finland
5Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

CORRESPONDING AUTHOR
Sampsa Hautaniemi, D Tech, Research Program in Systems Oncology, Research Programs Unit, Faculty of Medicine, P.O. Box 63, University of Helsinki, Helsinki, Finland; e-mail: sampsa.hautaniemi@helsinki.fi

EQUAL CONTRIBUTION
J.O. and K.Z. contributed equally to this work. A.F. and S.H. contributed equally to this work.

PRIOR PRESENTATION

SUPPORT
Supported by the European Union’s Horizon 2020 research and innovation program (Grant Agreement No 667403), the Academy of Finland (Project 305087), the Sigrid Jusélius Foundation, and Finnish Cancer Associations (all to S.H.).

AUTHOR CONTRIBUTIONS
Conception and design: Jaana Oikkonen, Seija Grénman, Rainer Lehtonen, Olli Carpen, Johanna Hynninen, Anniina Färrkilä, Sampsa Hautaniemi
Financial support: Seija Grénman, Sampsa Hautaniemi
Administrative support: Seija Grénman, Sampsa Hautaniemi
Provision of study material or patients: Sakari Hietanen, Seija Grénman, Olli Carpen, Johanna Hynninen
Collection and assembly of data: Liina Salminen, Kari Lavikka, Sakari Hietanen, Kaisa Huhtinen, Johanna Hynninen, Anniina Färrkilä
Data analysis and interpretation: Jaana Oikkonen, Kaiyang Zhang, Ingrid Schulman, Kari Lavikka, Noora Andersson, Erika Ojanperä, Sakari Hietanen, Olli Carpen, Johanna Hynninen, Anniina Färrkilä, Sampsa Hautaniemi
Manuscript writing: All authors
Final approval of manuscript: All authors
REFERENCES
